Thallion Pharmaceuticals Inc.

Presenter: Allan Mandylzys, CEO

Company Information

Company Type: Pharmaceuticals

Development Stage: Public

Company Profile

Thallion Pharmaceuticals Inc. is a publicly traded (TSX: TLN) biotechnology company focused on developing new treatments for under-served markets in oncology and infectious diseases. The Company's clinical-stage pipeline includes two oncology product candidates based on targeted therapies: TLN-4601, a small molecule and TLN-232, a synthetic peptide, both in phase II clinical trials in Glioblastoma Multiforme and Metastatic Melanoma, respectively. The Company's third product is Shigamabs®, a dual antibody product candidate for the treatment of Shigatoxin-mediated bacterial infections and is ready to enter phase II clinical testing. Thallion's proprietary technology platform, DECIPHER®, is a genomics-based discovery platform technology from which TLN-4601 was discovered. DECIPHER® is used to identify new chemical entities from environmental, non-pathogenic bacteria.

Presenter Bio

Dr. Mandelzys served as Vice President, Business Development for Labopharm Inc. from October 2000 to December 2006. He has extensive experience in the areas of pharmaceutical licensing, contract negotiations, strategic alliance management, intellectual property management and scientific operations. Prior to joining Labopharm, Dr. Mandelzys held several positions at Allelix Biopharmaceuticals Inc. (now NPS Pharmaceuticals) beginning with scientific roles of increasing responsibility and culminating as Director, Business Development. Dr. Mandelzys holds both a Ph.D. in physiology and an M.B.A. from McGill University and a B.Sc. from the University of Toronto. He received his post-doctoral training at the Roche Institute of Molecular Biology.

Contact

Thallion Pharmaceuticals Inc.
7150 Alexander Fleming
Montreal
Quebec, Canada
H4S 2C8

ph: 514-940-3618
fx: 514-228-3621

www.thallion.com
amandylzys@thallion.com